Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on Revvity. The associated price target was lowered to $115.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Puneet Souda has given his Buy rating due to a combination of factors including Revvity’s current trading valuation and its growth potential. Despite a reduction in revenue, margin, and EPS guidance primarily due to changes in China’s healthcare policy affecting the ImmunoDx segment, Revvity’s core reagents business showed some growth. The company’s current trading multiple is lower compared to its peers, suggesting limited downside risk. Additionally, Revvity’s software segment demonstrated significant growth, contributing positively to the overall outlook.
Puneet Souda also noted that management is taking strategic cost actions to improve operational margins by 2026, which could enhance profitability. Although challenges such as tariff costs and changes in reimbursement policies in China present headwinds, the company’s efforts to optimize its cost structure and leverage its software growth are seen as positive steps. These factors collectively support the Buy rating, with a revised price target reflecting the adjusted growth and margin expectations.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $108.00 price target.
RVTY’s price has also changed moderately for the past six months – from $125.590 to $95.040, which is a -24.33% drop .